**Author details**

Rakesh Mishra1 and Amit Agrawal<sup>2</sup> \*

1 Department of Neurosurgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India

2 Department of Neurosurgery, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India

\*Address all correspondence to: dramitagrawal@gmail.com

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**71**

*Primary Central Nervous System Neuroblastoma: An Enigmatic Entity*

2016;131(6): 803-820. https://doi. org/10.1007/s00401-016-1545-1.

[9] Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86(2): 364-372.

[10] Hsiao CC, Huang CC, Sheen JM, et al. Differential expression of delta-like gene and protein in neuroblastoma, ganglioneuroblastoma and ganglioneuroma. Mod Pathol. 2005;18(5): 656-662. https://doi.org/10.1038/

[11] Brodeur G, Castleberry R. Principles and Practice of Pediatric Oncology Pizzo PA and Poplack DG. Lippincott-

Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012;256(4): 573-580. https://doi.org/10.1097/SLA.0b013

modpathol.3800335.

e31826cbbbd.

2-m.

Raven: Philadelphia; 1997.

[12] Nuchtern JG, London WB,

[13] Carlsen NL, Christensen IJ,

Schroeder H, et al. Prognostic factors in neuroblastomas treated in Denmark from 1943 to 1980. A statistical estimate of prognosis based on 253 cases. Cancer. 1986;58(12): 2726-2735. https://doi. org/10.1002/1097-0142(19861215)58: 12<2726::aid-cncr2820581229>3.0.co;

[14] Stiller C, Parkin D. International variations in the incidence of

cancer. 1992;52(4): 538-543.

[15] London W, Castleberry R, Matthay K, et al. Evidence for an age cutoff greater than 365 days for

neuroblastoma. International journal of

neuroblastoma risk group stratification in the Children's Oncology Group. Journal of clinical oncology. 2005;23(27): 6459-6465.

*DOI: http://dx.doi.org/10.5772/intechopen.98244*

Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2: 16078. https://doi.org/10.1038/nrdp.2016.78.

Neuroblastoma. New England Journal of Medicine. 2010;362(23): 2202-2211. https://doi.org/10.1056/NEJMra0804577.

[3] Bonilla MA, Cheung NK. Clinical progress in neuroblastoma. Cancer Invest. 1994;12(6): 644-653. https://doi. org/10.3109/07357909409023049.

[4] Bianchi F, Tamburrini G, Gessi M, Frassanito P, Massimi L, Caldarelli M. Central nervous system (CNS) neuroblastoma. A case-based update. Child's Nervous System. 2018;34(5): 817-823. https://doi.org/10.1007/

[5] Vo KT, Matthay KK, Neuhaus J, et al. Clinical, biologic, and prognostic

differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014;32(28): 3169-3176. https://doi.org/10.1200/

[6] Horten BC, Rubinstein LJ. Primary cerebral neuroblastoma. A clinicopathological study of 35 cases. Brain. 1976; 99(4): 735-756. https://doi.org/10.1093/

[7] Bennett Jr JP, Rubinstein LJ. The biological behavior of primary cerebral neuroblastoma: A reappraisal of the clincal course in a series of 70 cases. Annals of Neurology. 1984;16(1): 21-27. https://doi.org/https://doi.org/10.1002/

[8] Louis DN, Perry A, Reifenberger G,

Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica.

et al. The 2016 World Health

s00381-018-3764-3.

jco.2014.56.1621.

brain/99.4.735.

ana.410160106.

**References**

[1] Matthay KK, Maris JM,

[2] Maris JM. Recent Advances in

*Primary Central Nervous System Neuroblastoma: An Enigmatic Entity DOI: http://dx.doi.org/10.5772/intechopen.98244*
